Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGTC NASDAQ:FENC NASDAQ:GMDA NASDAQ:LOGC NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/AFENCAdherex Technologies$8.78-2.9%$7.83$3.96▼$9.30$249.51M0.3992,760 shs109,351 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsLOGCLogicBio Therapeutics$7.26-0.1%$2.06$0.26▼$3.77$190.79M2.06168,718 shs41,380 shsVYGRVoyager Therapeutics$3.49-1.7%$3.20$2.65▼$9.55$196.44M0.85487,782 shs829,728 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%FENCAdherex Technologies-2.88%+1.09%+7.07%+75.25%+46.33%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%LOGCLogicBio Therapeutics-2.94%-0.41%+0.14%+8.18%+27.10%VYGRVoyager Therapeutics-1.69%+6.40%+3.25%+10.09%-56.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic Technologies0.1518 of 5 stars0.00.00.03.80.60.00.0FENCAdherex Technologies2.1955 of 5 stars3.61.00.00.02.03.30.0GMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/ALOGCLogicBio Therapeutics1.6729 of 5 stars0.05.00.04.70.60.80.6VYGRVoyager Therapeutics3.9865 of 5 stars3.62.00.04.62.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic Technologies 0.00N/AN/AN/AFENCAdherex Technologies 3.25Buy$13.0048.06% UpsideGMDAGamida Cell 0.00N/AN/AN/ALOGCLogicBio Therapeutics 0.00N/AN/AN/AVYGRVoyager Therapeutics 3.13Buy$13.39283.67% UpsideCurrent Analyst Ratings BreakdownLatest AGTC, FENC, VYGR, GMDA, and LOGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/14/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51FENCAdherex Technologies$47.54M5.10$0.03 per share279.91($0.21) per share-41.81GMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00LOGCLogicBio Therapeutics$287M0.66N/AN/A$8.96 per share0.81VYGRVoyager Therapeutics$80M2.41N/AN/A$5.49 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/AFENCAdherex Technologies-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)GMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/ALOGCLogicBio Therapeutics-$317M-$5.79N/A∞N/A-141.03%-81.98%-52.13%N/AVYGRVoyager Therapeutics-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)Latest AGTC, FENC, VYGR, GMDA, and LOGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025VYGRVoyager Therapeutics-$0.48N/AN/AN/A$9.50 millionN/A5/13/2025Q1 2025FENCAdherex Technologies-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million5/9/2025Q1 2025LOGCLogicBio TherapeuticsN/A-$0.27N/A-$0.27N/AN/A5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40FENCAdherex TechnologiesN/A5.134.97GMDAGamida Cell213.142.162.09LOGCLogicBio TherapeuticsN/A31.6031.60VYGRVoyager TherapeuticsN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%FENCAdherex Technologies55.51%GMDAGamida Cell50.34%LOGCLogicBio Therapeutics46.05%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%FENCAdherex Technologies11.76%GMDAGamida Cell3.40%LOGCLogicBio Therapeutics8.10%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableFENCAdherex Technologies1027.60 million24.35 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableLOGCLogicBio Therapeutics6226.28 million24.16 millionOptionableVYGRVoyager Therapeutics10055.34 million51.80 millionOptionableAGTC, FENC, VYGR, GMDA, and LOGC HeadlinesRecent News About These CompaniesUK awards AirTanker network node upgrade for VoyagerJuly 11 at 10:28 AM | janes.comJVoyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current TechnologyJuly 10 at 2:18 PM | msn.comBrokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.39July 8, 2025 | americanbankingnews.comRNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'July 7, 2025 | itv.comIAtlas Announces New Canadian Arctic Expedition Aboard World VoyagerJuly 6, 2025 | cruiseindustrynews.comCWith Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-WalletsJuly 5, 2025 | travelmole.comTVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesJuly 5, 2025 | marketbeat.comAnt International launches Alipay+ Voyager, an AI-powered travel assistant inside e-walletsJuly 3, 2025 | walastech.comWVYGR Voyager Therapeutics, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMajor Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With PaintJune 20, 2025 | theaviationist.comTProtesters Vandalize RAF Voyager Tankers In Palestine ProtestJune 20, 2025 | aviationweek.comAVoyager Technologies Soars with IPO SuccessJune 14, 2025 | devdiscourse.comDSpace Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss ExpansionJune 12, 2025 | devdiscourse.comDVoyager Technologies Rises in Debut, Signaling Improving IPO MarketJune 12, 2025 | msn.comVoyager soars 82% on first day of trading as defense tech boomsJune 12, 2025 | msn.comInvestor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOsJune 11, 2025 | msn.comVoyager Technologies' Shares More Than Double in NYSE DebutJune 11, 2025 | marketwatch.comVoyager Technologies Shares Soar In Market DebutJune 11, 2025 | news.crunchbase.comNSpace tech firm Voyager valued at $3.8 billion as shares surge in NYSE debutJune 11, 2025 | aol.comAVoyager raises $383 million from upsized IPOJune 11, 2025 | spacenews.comSSpace and defense tech firm Voyager raises $382.8 million in IPOJune 11, 2025 | fastcompany.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGTC, FENC, VYGR, GMDA, and LOGC Company DescriptionsApplied Genetic Technologies NASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Adherex Technologies NASDAQ:FENC$8.78 -0.26 (-2.88%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$8.76 -0.01 (-0.17%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Gamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.LogicBio Therapeutics NASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Voyager Therapeutics NASDAQ:VYGR$3.49 -0.06 (-1.69%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.65 +0.16 (+4.58%) As of 07/11/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
